The effect of cyclophosphamide on b and t lymphocytes in patients with connective tissue diseases
Open Access
- 1 January 1975
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 18 (1) , 67-75
- https://doi.org/10.1002/art.1780180113
Abstract
Absolute numbers of B (IgG-, IgM-, and IgA-staining) and T lymphocytes (sheep erythrocyte rosette-forming cells) were determined in patients with systemic lupus erythematosus and other connective tissue diseases in cyclophosphamide-treated and noncyclo-phosphamide-treated patients and in control subjects. In patients receiving cyclophosphamide, all three types of immunoglobulin-staining varieties of circulating B lymphocytes were significantly decreased. At the same time the circulating T lymphocytes were also significantly reduced. In patients with scleroderma trcated with therapeutic doses of cyclophosphamide and studied sequentially, the reduction in B lymphocytes oc-curred first, with eventual depletion of both cell types. In 2 patients, an early rebound increase in T cells occurred followed by a marked reduction. These data indicate that the immunosuppressive effects of cyclophosphamide may be associated with a reduction in both cell types.Keywords
This publication has 26 references indexed in Scilit:
- B cell and T cell lymphopenia in systemic lupus erythematosusCellular Immunology, 1974
- Parameters of improvement in patients with rheumatoid arthritis treated with cyclophosphamideArthritis & Rheumatism, 1974
- Rosette formation by peripheral blood lymphocytes in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1973
- Immunosuppressive and antiinflammatory properties of cyclophosphamide, azathioprine and methotrexateArthritis & Rheumatism, 1973
- SUBPOPULATIONS OF HUMAN PERIPHERAL BLOOD LYMPHOCYTES DISTINGUISHED BY COMBINED ROSETTE FORMATION AND MEMBRANE IMMUNOFLUORESCENCEThe Lancet, 1972
- Recent Developments in Immunofluorescence (with colour plates I and II)Published by S. Karger AG ,1972
- Immunologic effects of cyclophosphamide treatment in rheumatoid arthritisArthritis & Rheumatism, 1970
- ROLE OF CIRCULATING LEUCOCYTES IN CUTANEOUS LEPROSY: STUDIED BY CYCLOPHOSPHAMIDE-INDUCED LEUCOPENIAThe Lancet, 1964
- SUPPRESSION OF TISSUE IMMUNITY BY CYCLOPHOSPHAMIDETransplantation, 1964
- Effect of Cyclophosphoramide, 6-Mercaptopurine, Actinomycin D and Vincaleukoblastine on the Acquisition of Delayed Hypersensitivity (DNCB Contact Dermatitis) in the Guinea-Pig11From the Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia 4, Pennsylvania.This study was supported in part by U.S.P.H.S. Training Grant 2 G-62.This investigation was carried out during the tenure of a postdoctoral fellowship, held by Dr. Maibach, from the Division of General Medical Sciences, United States Public Health Service.Cyclophosphoramide (Cytoxan®) was supplied by Paul A. Walter, M.D., Mead Johnson Laboratories, Evansville 21, Indiana; 6-mercaptopurine by Donald S. Searle, M.D., Burroughs Wellcome & Co., Tuckahoe, N.Y.; vincaleukoblastine by J. A. Armstrong, M.D., Eli Lilly and Co., Indianapolis 6, Indiana; and Actinomycin D by Elmer Alpert, M.D., Merck Sharp and Dohme, West Point, Pa.Presented at the Twenty-second Annual Meeting of The Society for Investigative Dermatology, Inc., New York, N.Y., June 28, 1961.Journal of Investigative Dermatology, 1961